- Home
- WIA vs GNFT Comparison
WIA vs GNFT Comparison
Compare WIA & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- GNFT
- Stock Information
- Founded
- WIA 2003
- GNFT 1999
- Country
- WIA United States
- GNFT France
- Employees
- WIA N/A
- GNFT N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WIA Finance
- GNFT Health Care
- Exchange
- WIA Nasdaq
- GNFT Nasdaq
- Market Cap
- WIA 186.8M
- GNFT 179.7M
- IPO Year
- WIA N/A
- GNFT 2019
- Fundamental
- Price
- WIA $8.22
- GNFT $3.74
- Analyst Decision
- WIA
- GNFT Strong Buy
- Analyst Count
- WIA 0
- GNFT 1
- Target Price
- WIA N/A
- GNFT $13.00
- AVG Volume (30 Days)
- WIA 39.2K
- GNFT 9.9K
- Earning Date
- WIA 01-01-0001
- GNFT 09-19-2024
- Dividend Yield
- WIA 12.29%
- GNFT N/A
- EPS Growth
- WIA N/A
- GNFT N/A
- EPS
- WIA N/A
- GNFT 0.47
- Revenue
- WIA N/A
- GNFT $86,225,222.00
- Revenue This Year
- WIA N/A
- GNFT $145.20
- Revenue Next Year
- WIA N/A
- GNFT N/A
- P/E Ratio
- WIA N/A
- GNFT $7.89
- Revenue Growth
- WIA N/A
- GNFT 175.45
- 52 Week Low
- WIA $7.56
- GNFT $3.35
- 52 Week High
- WIA $8.91
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- WIA 59.46
- GNFT 49.41
- Support Level
- WIA $8.09
- GNFT $3.68
- Resistance Level
- WIA $8.21
- GNFT $4.03
- Average True Range (ATR)
- WIA 0.09
- GNFT 0.15
- MACD
- WIA 0.02
- GNFT 0.05
- Stochastic Oscillator
- WIA 73.33
- GNFT 57.35
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.